Burning Rock narrows losses with drug research as new driver
The cancer testing company has finally reduced the flow of red ink and is generating a growing income stream from drug research services Key Takeaways: Burning Rock's net loss…
BNR.US
Recent Articles
RELATED ARTICLES
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Junshi narrows its losses but delivers no cure for share price woes
1877.HK 688180.SHG
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
Discover hidden China stock gems in our weekly newsletter